Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Cancer Res. 2011 May 5;71(12):4192–4204. doi: 10.1158/0008-5472.CAN-10-2442

Figure 6.

Figure 6

A. Interferon-γ release by HLA-restricted CTLs recognizing NY-ESO-1 and MAGE-A3 in the context of HLA *A0201 after overnight incubation with H1299 or H1299-A2 targets (negative and positive controls, respectively).

B. Interferon-γ release by HLA-restricted CTLs specific for NY-ESO-1 and MAGE-A3 after overnight incubation with H2087, as well as H841-A2 and SAEC-A2. Targets represent untreated controls, or cells exposed to DAC (0.1μM), DZNep (0.5 μM) or DAC (0.1μM) –DZNep (0.5 μM). Data are representative of two independent experiments performed with two different PBL donors. * P<0.05, DAC vs untreated; † P<0.05, DAC-DZNep vs DAC; ‡ P<0.05 vs DZNep vs untreated.